MARKET

CRBU

CRBU

Caribou Biosciences, Inc.
NASDAQ
5.14
+0.02
+0.29%
Opening 12:04 03/28 EDT
OPEN
5.15
PREV CLOSE
5.12
HIGH
5.23
LOW
5.07
VOLUME
494.66K
TURNOVER
0
52 WEEK HIGH
8.59
52 WEEK LOW
3.440
MARKET CAP
463.76M
P/E (TTM)
-3.7132
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CRBU last week (0318-0322)?
Weekly Report · 3d ago
32 “Breakthroughs” stocks by BofA - Part 2
Tech 32 “Breakthroughs” stocks by BofA Securities published a list of 32 companies that its analysts believe will benefit from breakthroughs. These 32 stocks have a combined market cap of $16T. The list includes companies in the healthcare, communications, and energy sectors.
Seeking Alpha · 03/21 15:53
Caribou Biosciences Price Target Raised to $24.00/Share From $23.00 by HC Wainwright & Co.
Dow Jones · 03/19 10:36
Caribou Biosciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/19 10:36
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fusion Pharmaceuticals (FUSN), Caribou Biosciences (CRBU) and Neurogene (NGNE)
Fusion Pharmaceuticals, Caribou Biosciences and Neurogene have received a lot of coverage today. Fusion Pharmaceuticals received a Hold rating and a $21.00 price target from Leerink Partners analyst Faisal Khurshid. The Healthcare sector has been in the spotlight as analysts recommend companies in the sector.
TipRanks · 03/19 10:30
HC Wainwright & Co. Maintains Buy on Caribou Biosciences, Raises Price Target to $24
Benzinga · 03/19 10:26
Weekly Report: what happened at CRBU last week (0311-0315)?
Weekly Report · 03/18 09:13
Caribou Biosciences (NASDAQ:CRBU): Recent Price Volatility May Offer Investors an Entry Point
TipRanks · 03/14 18:29
More
About CRBU
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity. Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate.

Webull offers Caribou Biosciences Inc stock information, including NASDAQ: CRBU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRBU stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRBU stock methods without spending real money on the virtual paper trading platform.